natgillin/translations-raw huggingface dataset:
Ca. halvdelen af patienterne i hver behandlingsgruppe havde hormonreceptor-positiv sygdom (defineret som østrogenreceptor-positiv og/eller progesteronreceptor-positiv), og ca. halvdelen af patienterne i hver behandlingsgruppe havde tidligere fået adjuverende eller neoadjuverende behandling.
Approximately half the patients in each treatment group had hormone receptor-positive disease (defined as estrogen receptor (ER) positive and/or progesterone receptor (PgR) positive) and approximately half of the patients in each treatment group had received prior adjuvant or neoadjuvant therapy.
Ca. halvdelen af patienterne i hver behandlingsgruppe havde østrogenreceptor-positiv og/eller progesteronreceptor- positiv sygdom.
Approximately half the patients in each treatment group had ER-positive and/or PgR-positive disease.
Ca. halvdelen af patienterne med metastatisk kræft i tyktarmen eller endetarmen har vildtype-RAS-tumorer.
About half of the patients with metastatic cancer of the colon or rectum have wild-type RAS tumours.
Ca. halvdelen af radioaktiviteten, der blev administreret oralt som [14C]netupitant, blev genfundet i urin og fæces inden for 120 timer efter dosering.
Approximately half the radioactivity administered orally as [14C]­netupitant was recovered from urine and faeces within 120 h of dosing.
Ca. to tredjedele af patienterne opnåede et virusindhold på mindre end 50 kopier/ml og fastholdt dette efter 48 uger.
Around two-thirds of the patients achieved and maintained viral loads below 50 copies/ml after 48 weeks.
CA225025: Dette randomiserede studie med patienter med metastatisk kolorektal cancer, som tidligere havde fået behandling med oxaliplatin, irinotecan plus fluoropyrimidin for metastatisk sygdom, sammenlignede kombinationen af cetuximab som enkeltstof sammen med "bedste understøttende pleje" ("best supportive care", BSC) (287 patienter) med "bedste understøttende pleje" alene (285 patienter).
CA225025: This randomised study in patients with metastatic colorectal cancer who had received prior oxaliplatin-, irinotecan- and fluoropyrimidine-based treatment for metastatic disease compared the addition of cetuximab as a single agent to best supportive care (BSC) (287 patients) with best supportive care (285 patients).
Cabazitaxel AUC: ↑ 1,3 gange
Cabazitaxel AUC: ↑ 1.3-fold
Cabazitaxel hæmmede transporten af P-glykoprotein (PgP) (digoxin, vinblastin), Breast-Cancer-Resistance Proteiner (BCRP) (methotrexat) og organisk anion- transporterende polypeptid OATP1B3 (CCK8) ved koncentrationer, der var mindst 15 gange højere end under kliniske forhold, hvorimod det hæmmede transporten af OATP1B1 (estradiol-17β- glukuronid) ved koncentrationer kun 5 gange højere end under kliniske forhold.
Cabazitaxel inhibited the transport of P-glycoprotein (PgP) (digoxin, vinblastin), Breast-Cancer-Resistant-Proteins (BCRP) (methotrexate) and Organic Anion Transporting Polypeptide OATP1B3 (CCK8) at concentrations at least 15 fold what is observed in clinical setting while it inhibited the transport of OATP1B1 (estradiol-17β-glucuronide) at concentrations only 5 fold what is observed in clinical setting.
Cabazitaxel metaboliseres ekstensivt i leveren (> 95 %), hovedsageligt af CYP3A-isoenzymet (80- 90 %).
Cabazitaxel is extensively metabolised in the liver (>95%), mainly by the CYP3A isoenzyme (80% to 90%).
Cabazitaxel virker ved at hæmme kræftcellernes evne til at nedbryde deres interne "skelet", som gør det muligt for dem at dele sig og formere sig.
Cabazitaxel works by blocking the ability of cancer cells to break down their internal ‘skeleton’ that allows them to divide and multiply.
Cabergolin .........................................................................
Cabergoline .......................................................................
cabergolin lisurid, pergolid: risiko for vasokonstriktion og øget blodtryk
cabergoline lisuride, pergolide: risk of vasoconstriction and increase in blood pressure.
CABG: Koronar bypasskirurgi, GUSTO: Global Use of Strategies to Open Coronary Arteries (Global anvendelse af strategier til åbne koronararterier); u/: uden a I den sammenlagte CHAMPION-analyse blev GUSTO Mild defineret som anden blødning, der ikke kræver blodtransfusion eller forårsager hæmodynamisk kompromis b I CHAMPION PHOENIX blev GUSTO Mild defineret som anden blødning, der kræver indgreb, men ikke kræver blodtransfusion eller forårsager hæmodynamisk kompromis
CABG: Coronary Artery Bypass Graft Surgery; GUSTO: Global Use of Strategies to Open Coronary Arteries; w/o: without a In the CHAMPION pooled analysis, GUSTO Mild was defined as other bleed not requiring blood transfusion or causing haemodynamic compromise b In CHAMPION PHOENIX, GUSTO Mild was defined as other bleeding requiring intervention but not requiring blood transfusion or causing haemodynamic compromise
CABOMETYX 20 mg filmovertrukne tabletter cabozantinib
CABOMETYX 20 mg film-coated tablets cabozantinib
CABOMETYX 20 mg filmovertrukne tabletter er gule og runde, uden delekærv og præget med "XL" på den ene side og "20" på den anden side.
CABOMETYX 20 mg film-coated tablets are yellow, round with no score, and identified with “XL” on one side and “20” on the other side.
CABOMETYX 40 mg filmovertrukne tabletter cabozantinib
CABOMETYX 40 mg film-coated tablets cabozantinib
CABOMETYX 60 mg filmovertrukne tabletter cabozantinib
CABOMETYX 60 mg film-coated tablets cabozantinib
CABOMETYX 60 mg filmovertrukne tabletter EU/1/16/1136/005
Cabometyx 60 mg film-coated tablets EU/1/16/1136/005
Cabometyx blev i undersøgelsen sammenlignet med kræftmidlet everolimus.
In the study, Cabometyx was compared with the cancer medicine everolimus.
Cabometyx er et lægemiddel mod kræft, der anvendes til at behandle voksne patienter med fremskredent renalcellekarcinom (en type nyrekræft), som tidligere er blevet behandlet med et kræftmiddel, der kaldes "vaskulær endotelial vækstfaktor (VEGF)-hæmmer".
Cabometyx is a cancer medicine used to treat adults with advanced renal cell carcinoma (a type of kidney cancer) who have been previously treated with a type of cancer medicine called a ‘vascular endothelial growth factor (VEGF) inhibitor’.
CABOMETYX er indiceret til behandling af voksne patienter med fremskredent nyrecellekarcinom (RCC) efter tidligere behandling med målrettet vaskulær endotelial vækstfaktor (VEGF).
CABOMETYX is indicated for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy
CABOMETYX er til oral anvendelse.
CABOMETYX is for oral use.
Cabometyx er undersøgt i en hovedundersøgelse, hvori deltog 658 voksne med fremskredent renalcellekarcinom, som var blevet værre på trods af behandling med en VEGF-hæmmer.
Cabometyx has been investigated in one main study involving 658 adults with advanced renal cell carcinoma that had got worse despite treatment with a VEGF inhibitor.
Cabometyx indeholder lactose og bør ikke anvendes til patienter med arvelig galactoseintolerans, en særlig form af arvelig lactasemangel (Lapp Lactase deficiency) eller glucose/galactosemalabsorption.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine.
Cabometyx udleveres kun efter recept, og behandlingen bør kun iværksættes af en læge med erfaring i brug af kræftmedicin.
Cabometyx can only be obtained with a prescription and treatment should be started by a doctor who has experience in using cancer medicines.
CABOMETYX’s sikkerhed og virkning blev evalueret i et randomiseret, åbent fase III-multicenterstudie.
The safety and efficacy of CABOMETYX were evaluated in a randomized, open-label, multicenter Phase 3 study.
Cabozantinib anbefales ikke til patienter med svært nedsat leverfunktion, da sikkerheden og virkningen ikke er blevet fastslået hos denne population.
Cabozantinib is not recommended for use in patients with severe hepatic impairment as safety and efficacy have not been established in this population.
Cabozantinib anbefales ikke til patienter med svært nedsat leverfunktion, da sikkerheden og virkningen ikke er blevet fastslået hos denne population.
Cabozantinib is not recommended for use in subjects with severe hepatic impairment as safety and efficacy have not been established in this population.
Cabozantinib bør anvendes med forsigtighed til patienter med en anamnese for forlængelse af QT- interval, patienter, der tager anti-arytmetika, eller patienter med præ-eksisterende hjertelidelse, bradykardi eller elektrolytforstyrrelser.
Cabozantinib should be used with caution in patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances.
Cabozantinib er et lille molekyle, der hæmmer multiple receptor-tyrosinkinaser (RTK’er) impliceret i tumorvækst og angiogenese, patologisk knogleremodellering, lægemiddelresistens og metastatisk progression af cancer.
Cabozantinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumour growth and angiogenesis, pathologic bone remodeling, drug resistance, and metastatic progression of cancer.
Cabozantinib er et lille molekyle, der hæmmer multiple receptortyrosinkinaser (RTK’er) impliceret i tumorvækst og angiogenese, patologisk knogle genmodellering og metastatisk progression af cancer.
Cabozantinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumour growth and angiogenesis, pathologic bone remodeling, and metastatic progression of cancer.
Cabozantinib har ikke udvist noget mutagent eller clastogent potentiale i et standardbatteri af genotoksicitetsbestemmelser.
Cabozantinib has shown no mutagenic or clastogenic potential in a standard battery of genotoxicity assays.
Cabozantinib kan derfor have potentialet til at øge plasmakoncentrationerne af co-administrerede substrater P-gp.
Therefore, cabozantinib may have the potential to increase plasma concentrations of co-administered substrates of P-gp.
Cabozantinib skal anvendes med forsigtighed til patienter med tforlænget QT-interval i anamnesen, patienter, som tager antiarytmika, og patienter med allerede eksisterende hjertesygdom, bradykardi eller elektrolytforstyrrelser.
Cabozantinib should be used with caution in patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances.
Cabozantinib skal seponeres hos patienter, der får gastrointestinal perforation eller en fistel, der ikke kan behandles tilfredsstillende.
Cabozantinib should be discontinued in patients who experience a GI perforation or a fistula that cannot be adequately managed .
Cabozantinib skal seponeres hos patienter, som udvikler akut myokardieinfarkt eller nogen anden klinisk signifikant arteriel tromboembolisk komplikation.
Cabozantinib should be discontinued in patients who develop an acute myocardial infarction or any other clinically significant arterial thromboembolic complication.
Cabozantinib var en hæmmer (IC50 = 7,0 μM), men ikke et substrat, af P-gp transportaktiviteter i et to- rettet assay-system, der anvender MDCK-MDR1 celler.
Cabozantinib was an inhibitor (IC50 = 7.0 μM), but not a substrate, of P-gp transport activities in a bi-directional assay system using MDCK-MDR1 cells.
CAD
EXP
CAD:
EXP
Cada comprimido contiene 1.000 mg de hidroxicarbamida.
Each film-coated tablet contains 1,000 mg of hydroxycarbamide.
Cada comprimido contiene 100 mg de hidroxicarbamida.
Each film-coated tablet contains 100 mg of hydroxycarbamide.
Cada comprimido contiene 100 mg de hidroxicarbamida.
Each tablet contains 100 mg of hydroxycarbamide.
Cada comprimido contiene 1000 mg de hidroxicarbamida.
Each tablet contains 1,000 mg of hydroxycarbamide.
Cada comprimido recubierto con pelicula de Siklos 1000 mg contiene 1.000 mg de hidroxicarbamida.
Each Siklos 1000 mg film-coated tablet contains 1,000 mg hydroxycarbamide.
Cada comprimido recubierto con película de Siklos 100 mg contiene 100 mg de hidroxicarbamida.
Each Siklos 100 mg film-coated tablet contains 100 mg hydroxycarbamide.
Cada comprimido tendrá grabado “100” en una cara.
Each tablet is embossed 100 on one side.
Caelyx 2 mg/ml koncentrat til infusionsvæske, opløsning pegyleret liposomal doxorubicin hydrochlorid
Caelyx 2 mg/ml concentrate for solution for infusion Pegylated liposomal doxorubicin hydrochloride
Caelyx anvendes også til at give en forbedring af Deres Kaposis sarkom blandt andet ved lindring, lettelse og endog formindskelse af canceren.
Caelyx is also used to produce an improvement in your Kaposi’s sarcoma including flattening, lightening and even shrinkage of the cancer.
Caelyx bør håndteres og bortkastes i henhold til retningslinjerne for håndtering af andre lægemidler mod kræft.
Caelyx must be handled and disposed of in a manner consistent with that of other anticancer medicinal products.
Caelyx er en langtidscirkulerende pegyleret liposomal formulering af doxorubicin hydrochlorid.
Caelyx is a long-circulating pegylated liposomal formulation of doxorubicin hydrochloride.
Caelyx er indiceret:
Caelyx is indicated:
Caelyx farmakokinetik bestemt i et lille antal patienter med forhøjede total-bilirubin værdier afviger ikke fra patienter med normal total-bilirubin; indtil flere erfaringer er opnået, bør Caelyx dosis i patienter med nedsat leverfunktion imidlertid reduceres baseret på erfaringen fra de kliniske ovarieundersøgelsesprogrammer for bryst- og ovariecancer som følger: hvis bilirubin er mellem 1,2 – 3,0 mg/dl ved initiering af behandlingen, reduceres den første dosis med 25 %.
Caelyx pharmacokinetics determined in a small number of patients with elevated total bilirubin levels do not differ from patients with normal total bilirubin; however, until further experience is gained, the Caelyx dosage in patients with impaired hepatic function should be reduced based on the experience from the breast and ovarian clinical trial programs as follows: at initiation of therapy, if the bilirubin is between 1.2-3.0 mg/dl, the first dose is reduced by 25%.
Caelyx har ingen eller ubetydelig indflydelse på evnen til at føre bil eller betjene maskiner.
Caelyx has no or negligible influence on the ability to drive and use machines.
Caelyx indgives intravenøst i en dosis på 20 mg/m2 hver anden til tredje uge.
Caelyx is administered intravenously at 20 mg/m2 every two-to-three weeks.
Caelyx indgives intravenøst i en dosis på 50 mg/m2 én gang hver fjerde uge, så længe sygdommen ikke progredierer, og patienten fortsætter med at tolerere behandlingen.
Caelyx is administered intravenously at a dose of 50 mg/m2 once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.
Caelyx kan, som andre doxorubicin hydrochlorid-præparater, potensere toksiciteten af anden cancerbehandling.
Caelyx, like other doxorubicin hydrochloride preparations, may potentiate the toxicity of other anti-cancer therapies.
CAELYX KARTON 20 mg/10 ml - 1 hætteglas CAELYX KARTON 20 mg/10 ml - 10 hætteglas
CAELYX CARTON 20 mg/10 ml – 1 vial CAELYX CARTON 20 mg/10 ml – 10 vials
CAELYX KARTON 50 mg/25 ml - 1 hætteglas CAELYX KARTON 50 mg/25 ml - 10 hætteglas
CAELYX CARTON 50 mg/25 ml – 1 vial CAELYX CARTON 50 mg/25 ml – 10 vials
Caelyx må ikke anvendes til behandling af Kaposis sarkom, der kan behandles effektivt med lokal behandling, der kun virker på tumorstedet, eller med alfa-interferon- behandling af hele kroppen.
Caelyx must not be used to treat Kaposi’s sarcoma that could be treated effectively with ‘local’ treatments that only affect the site of the tumour or with whole-body alfa interferon treatment.
Caelyx må ikke anvendes til børn og unge, da det ikke vides, hvordan medicinen vil påvirke dem.
Caelyx should not be used in children and adolescents, because it is not known how the medicine will affect them.
Caelyx må ikke ombyttes med andre formuleringer af doxorubicin hydrochlorid.
Caelyx should not be used interchangeably with other formulations of doxorubicin hydrochloride.
Caelyx resulterede i let til moderat ovarie og testis atrofi i mus efter en enkelt dosis på 36 mg/kg.
Caelyx resulted in mild to moderate ovarian and testicular atrophy in mice after a single dose of 36 mg/kg.
Caelyx skal gives under nøje overvågning af en læge, der er specialiseret i anvendelsen af cellegifte.
Caelyx should be given under the supervision of a doctor who is qualified in the use of cytotoxic (cell- killing) medicines.
Caelyx skal håndteres og bortskaffes i henhold til retningslinjerne for håndtering af andre lægemidler mod cancer i overensstemmelse med lokale krav.
Caelyx must be handled and disposed of in a manner consistent with that of other anticancer medicinal products in accordance with local requirements.
Caelyx udviser enestående farmakokinetiske egenskaber og må ikke ombyttes med andre formuleringer af doxorubicin hydrochlorid.
Caelyx exhibits unique pharmacokinetic properties and must not be used interchangeably with other formulations of doxorubicin hydrochloride.
Caelyx vil blive givet af Deres læge direkte i en vene gennem et drop (som infusion).
Caelyx will be given to you by your doctor in a drip (infusion) into a vein.
Caelyx-dosen fortyndes i 250 ml 5 % (50 mg/ml) glucose infusionsvæske og indgives som intravenøs infusion over 30 minutter.
The dose of Caelyx is diluted in 250 ml 5% (50 mg/ml) glucose solution for infusion and administered by intravenous infusion over 30 minutes.
Caffein har forlænget halveringstid hos præmature nyfødte børn, og der er potentiel risiko for akkumulering, hvilket kan gøre det nødvendigt at monitorere behandlede spædbørn i en længere periode (se pkt.
Caffeine has a prolonged half-life in premature newborn infants and there is potential for accumulation which may necessitate monitoring infants treated for an extended period (see section 5.2).
Caffein og teofyllin må ikke anvendes sideløbende
That caffeine and theophylline should not be used concurrently
Caffein virker primært som et CNS-stimulerende middel.
Caffeine’s main action is as a CNS stimulant.
Caffeinbehandlingen reducerede hyppigheden af bronkopulmonal dysplasi [odds ratio (95 % CI) 0,63 (0,52 til 0-76)] og forbedrede overlevelsesraten uden invaliderende neuroudvikling [odds ratio (95 % CI) 0,77 (0,64 til 0,93)].
Caffeine therapy reduced the rate of bronchopulmonary dysplasia [odds ratio (95%CI) 0.63 (0.52 to 0-76)] and improved the rate of survival without neurodevelopmental disability [odds ratio (95%CI) 0.77 (0.64 to 0.93)].
Calcitonin er indiceret til:
Calcitonin is indicated for:
Calcitonin reducerer markant knogleomsætningen i tilstande med øget knogleresorptionshastighed, såsom Paget’s sygdom og akut knogletab på grund af pludselig immobilisering.
Calcitonin markedly reduces bone turnover in conditions with an increased rate of bone resorption such as Paget ‘s disease and acute bone loss due to sudden immobilisation.
Calcitonin responsa
Calcitonin Responsea
Calcium i serum
Serum calcium
Calcium Natrium Kalium Chlorid Karbamid
Calcium Sodium Potassium Chloride Urea
Calcium-antagonister
Beta2-adrenoceptor agonist (long acting)
Calcium-antagonister
Calcium channel blockers
Calcium-EDTMP natriumsalt (som Ca) Total natrium (som Na)
Calcium-EDTMP sodium salt (as Ca) Total sodium (as Na)
Calcium-kinetik.
Calcium kinetics.
calciumantagonist, f. eks. amlodipin, som bruges til at nedsætte blodtrykket
calcium channel blockers (e.g. amlodipine), used to treat raised blood pressure
Calciumantagonister
Calcium antagonists
Calciumantagonister
Calcium channel antagonists
Calciumantagonister
Calcium Channel Blockers
calciumantagonister (bepridil, verapamil, diltiazem) cholinesterasehæmmere (rivastigmin, physostigmin);
calcium channel blockers (bepridil, verapamil, diltiazem) cholinesterase inhibitors (rivastigmine, physostigmine);
Calciumantagonister (c)
Calcium antagonists (c)
Calciumantagonister (fx diltiazem, felodipin, nicardipin, nifedipin, verapamil)
Calcium channel blockers (e.g. diltiazem, felodipine, nicardipine, nifedipine, verapamil)
Calciumantagonister metaboliseret via CYP3A4 (f.eks. diltiazem, verapamil, nifedipin, nisoldipin): Der anbefales hyppig monitorering for bivirkninger og toksicitet relateret til calciumantagonister ved administration sammen med posaconazol.
Calcium channel blockers metabolised through CYP3A4 (e.g. diltiazem, verapamil, nifedipine, nisoldipine): Frequent monitoring for adverse events and toxicity related to calcium channel blockers is recommended during co-administration with posaconazole.
Calciumantagonister såsom bepridil (mod hjerteproblemer)
Calcium channel blockers such as bepridil (for heart problems)
Calciumantagonister, inklusive amlodipin, bør anvendes med forsigtighed til patienter med hjertesvigt, da de kan øge risikoen for nye kardiovaskulære hændelser og mortalitet.
Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.
calciumantagonisterne.
concentrations of calcium channel
calciumcarbonat
hydroxide; calcium
Calciumchlorid dihydrat Natriumhydroxid Saltsyre
Calcium chloride dihydrate Sodium hydroxide Hydrochloric acid
Calciumchlorid Polysorbat 80
Sodium chloride Calcium chloride Polysorbate 80
Calciumchlorid, dihydrat Simeticone
Calcium chloride, dihydrate Simeticone
Calciumchlorid, humant albumin, natriumchlorid, natriumcitrat, saccharose, trometamol
Calcium chloride, human albumin, sodium chloride, sodium citrate, sucrose, trometamol
Calciumholdige fosfatbindere, D-vitamin-steroler og/eller justering af calciumkoncentrationerne i dialysevæsken kan bruges til at øge serumcalcium iht. klinisk vurdering.
Calcium-containing phosphate binders, vitamin D sterols and/or adjustment of dialysis fluid calcium concentrations can be used to raise serum calcium according to clinical judgment.
Calciumhydrogenphosphat, vandfri Cellulose, mikrokrystallinsk
Calcium hydrogen phosphate anhydrous Cellulose, microcrystalline
Calciumhydrogenphosphat, vandfri Croscarmellosenatrium
Calcium Hydrogen Phosphate Anhydrous Croscarmellose Sodium
Calciumhydrogenphosphat, vandfrit Siliciumdioxid, kolloid vandfri Kaliumpolacrilin
Calcium hydrogen phosphate, anhydrous Colloidal silicon dioxide, anhydrous Polacrilin potassium
Calciumhydrogenphosphatdihydrat Cellulose, mikrokrystallinsk Crospovidon (type A) Hydroxypropylcellulose (L)
Calcium hydrogen phosphate dihydrate Microcrystalline Cellulose Crospovidone type A Hydroxypropylcellulose (L)
Calciumkanalblokkere
cobicistat.
calciumkanalblokkere (bruges til behandling af hjertekramper eller forstyrrelser i hjerterytmen),
calcium channel blockers (used in the treatment of anger or troubles of heart rhythm),
Calciumkanalblokkere (f.eks. diltiazem, felodipin, nicardipin, nifedipin, verapamil)
Calcium channel blockers (e.g. diltiazem, felodipine, nicardipine, nifedipine, verapamil)
calciumkanalblokkerne bør
should be considered.
Calciumkanalerne er porer, der tillader calcium at strømme ind i nervecellerne, hvorved der kan overføres elektriske impulser mellem nervecellerne.
These are pores which let calcium move into the nerve cells allowing electrical impulses to be transmitted between nerve cells.
Calciumphosphat, dibasisk, vandfrit
Calcium phosphate dibasic anhydrous
Calciumsalte: Thiaziddiuretika kan øge serum-calciumniveauet på grund af nedsat udskillelse.
Calcium salts: thiazide diuretics may increase serum calcium levels due to decreased excretion.
Calciumsilicat Magnesiumstearat
Calcium silicate Magnesium stearate
Calciumsilicat Magnesiumstearat (E572)
Calcium silicate Magnesium stearate (E572)
Calciumsilikat Magnesiumstearat
Calcium silicate Magnesium stearate.
Calciumtilskud
Calcium supplements